GlobalData analysts have identified 18 emerging immune checkpoint targets that are currently in clinical development. When looking at the cumulative number of clinical trials with immune checkpoint modulators from 2010 to Q2 2017, two companies, Bristol-Myers Squibb and Incyte, stand out as the main developers of emerging immune checkpoint modulators.
In Q2 2017, Bristol-Myers Squibb’s emerging checkpoint modulators were being explored in 33 clinical trials in Phase I to III, based on the clinical assessment of eight different drugs. Each of these eight products are associated with different emerging immune checkpoint targets, including indoleamine 2, 3-dioxygenase 1 (IDO1) and lymphocyte-activation gene 3 (LAG3) targets.
Based on the same cut-off point, Incyte’s emerging checkpoint modulators were evaluated in 26 clinical trials. In this period, Incyte developed fewer drugs than Bristol-Myers Squibb, with only three drugs covering three different targets. GlobalData’s analysis reveals that this high trial number is associated with the extensive clinical development of Incyte’s IDO1 inhibitor, epacadostat, across tumor types.
GlobalData (2017). PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities, August 2017, GDHC009PFR.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData